Anthem Biosciences, a company in the Biotechnology industry, reported revenue of ₹594 crore and net profit of ₹211 crore for the September 2026 quarter.
Anthem Biosciences (NSE: ANTHEM) closed at ₹951.05 on 20 Nov 2026, up 46.9% over the past year. Its market capitalisation is ₹53,589 crore and it trades at 84.9 times earnings.
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.